Serono Onercept Psoriasis Studies Discontinued Due To Safety Concerns

Serono is discontinuing development of its anti-tumor necrosis factor agent onercept for moderate-to-severe psoriasis based on cases of sepsis reported during Phase III trials, the company said April 6